





Ke	Nam	Paramet	Gat
	aCD3	FL2-	G
	aNI	FL2-	G

Fig. 1



125I-cHH1 Daudi
Ab/cell
4,00E+05
3,50E+05
3,00E+05
2,50E+05
2,00E+05
1,50E+05
1,00E+05
5,00E+04
0,00E+00
0
0,5
1
1,5
2
2,5
Time (hours)
100 ng/ml
1000 ng/ml
5000 ng/ml

Fig. 2



% antibody dependent cell cytotoxicity
20
15
10
5
0
chHH1
rituximab

Fig. 3



% specific lysis
0
20
40
60
80
100
120
140
40:1
20:1
10:1
no mAb
HH1 (20 ug/ml)
rituximab (20 ug/ml)
chHH1.1 (20 ug/ml)
chHH1.1 and rituximab (20 ug/ml each)

Fig. 4



% specific lysis
0
1
2
3
4
5
6
7
no mAb
HH1 (20 ug/ml)
rituximab (20 ug/ml)
chHH1.1 (20 ug/ml)
chHH1.1 and rituximab (20 ug/ml each)

Fig. 5



% of Injected dosage/g tissue
0
2
4
6
8
10
12
14
Urine
Blood
Lung
Heart
Liver
Spleen
Kidneys
Stomach
Small int.
Large int.
Femur
Muscle
Brain
Skull
Lymph nodes
24 hr
48 hr

Fig. 6



% specific lysis
0
10
20
30
40
50
60
70
80
20 ug/ml chHH1.3
20 ug/ml chHH1.3 and 20 ug/ml rituximab
no mAb
10:1 ind 1
15:1 ind 2

Fig. 7